StockTipsArenaBeta

BUY Glenmark Pharmaceuticals — Sachin Janardan Sarvade, IDBI Capital Markets and Securities

BUYGlenmark Pharmaceuticals
Glenmark Pharmaceuticals share price target & all analyst calls

bySachin Janardan Sarvade, IDBI Capital Markets and SecuritiesHorizon: NA (inferred Swing (≤2wk))3 Nov 2026via NDTV Profit

Entry₹2,370.5Inferred
Target₹2,950
Total upside +24.45%
Stop loss₹2,099-11.45% risk
CMP₹2,5901d ago
Active+9.26%+13.90%upside left 10d left
Follow Sachin Janardan Sarvade for new calls(15% target hit, 91 closed calls)Get alertsWatch GLENMARK for new buy/sell callsGet alertsSee 203 other Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 7 Nov, 5:28 pm IST
4 supporting2 neutral2 opposing
Supports the BUY call (4)

MACD above its signal line — bullish momentum

Technicals · macd·7 Nov · today

Glenmark Pharma shares will react to better-than-expected US sales in Q2, 14% growth in India biz

NewsCnbc-Tv18·6 Nov · yesterday

(opens in new tab)

Past week's volume 2.2× the 30-day average

Technicals · volume·6 Nov · yesterday

Glenmark stock: US distribution hub expands supply chain

NewsGoogle News·30 Oct · 1w ago

(opens in new tab)
Neutral / worth noting (2)

Glenmark Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.

NSE · Outcome of Board Meeting·5 Nov · 2d ago

(opens in new tab)

Ichnos Glenmark Innovation will present updated clinical data for ISB 2001 at the 68th ASH Annual Meeting.

BSE · Company Update·4 Nov · 2d ago

(opens in new tab)
Weighs against the BUY call (2)

RSI at 79 — overbought territory

Technicals · rsi·7 Nov · today

Glenmark Pharma Q2 Results: Net profit plunges 56% to Rs 264 crore, revenue down at Rs 4,247 cr

NewsEt-Markets·5 Nov · yesterday

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Glenmark Pharmaceuticals

All analyst calls on Glenmark Pharmaceuticals

More from Sachin Janardan Sarvade, IDBI Capital Markets and Securities

Every call and its outcome